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Abstract 
Amyloid β-peptides (Aβ) are a major hallmark of Alzheimer’s disease (AD) and their 
neurotoxicity develop with cytosolic calcium dysregulation. On the other hand, calmodulin (CaM), a 
protein which plays a major multifunctional role in neuronal calcium signaling, has been shown to be 
involved in the regulation of non-amyloidogenic processing of amyloid β precursor protein (APP). Using 
fluorescent 6-bromoacetyl-2-dimethylaminonaphthalene derivatives of CaM, Badan-CaM, and human 
amyloid β(1-42) HiLyte™-Fluor555, we show in this work that Aβ binds with high affinity to CaM 
through the neurotoxic Aβ25-35 domain. In addition, the affinity of Aβ for calcium-saturated CaM 
conformation is approximately 20-fold higher than for CaM conformation in the absence of calcium (apo-
CaM). Moreover, the value of Kd of 0.98±0.11 nM obtained for Aβ1-42 dissociation from CaM saturated 
by calcium point out that CaM is one of the cellular targets with highest affinity for neurotoxic Aβ 
peptides. A major functional consequence of Aβ-CaM interaction is that it slowdowns Aβ fibrillation. The 
novel and high affinity interaction between calmodulin and Aβ shown in this work opens a yet-unexplored 
gateway to further understand the neurotoxic effect of Aβ in different neural cells and also to address the 
potential of calmodulin and calmodulin-derived peptides as therapeutic agents in AD. 
 
Keywords: Amyloid β, Calmodulin, Badan-Calmodulin, Human amyloid β (1-42) HiLyte™-Fluor555, 
Calcium, Alzheimer’s disease. 
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1. Introduction 
 
A progressive loss of functional synapses has been noticed in hippocampal and cortical brain regions 
of patients with symptoms ranging from mild cognitive impairment (MCI) to early-mild Alzheimer’s 
disease (AD) [1; 2]. The 42-residue-long amyloid β-peptide (Aβ1-42) is remarkably involved in AD. This 
peptide is prone to aggregation and also impairs synaptic function at both pre- and postsynaptic sites, 
although excitatory post-synapses are likely its early targets [3]. In addition, intracellular calcium 
homeostasis has been shown to be disrupted in both sporadic and familial forms of AD, and this can 
exacerbate Aβ formation and promote tau hyperphosphorylation [4; 5]. Dysregulation of intracellular Ca2+ 
buffering by Aβ can trigger a pathogenic feed-forward cycle leading to an altered synaptic morphology, to 
neuronal apoptosis, and eventually to cognitive impairment [6].  
Calmodulin (CaM) plays a major role in neuronal calcium signaling, as a primary calcium binding 
protein relevant in cytosolic calcium buffering and also as a regulatory protein of other key effector 
proteins in calcium signaling pathways, reviewed in [7; 8; 9]. Noteworthy, nearly 30-years ago it was 
noticed that CaM is significantly decreased in the brain of AD individuals [10]. O’Day and Myre (2004) 
[11] raised the “calmodulin hypothesis” for late onset AD when they noticed that several proteins linked 
to the production of Aβ possess putative calmodulin binding domains (CaMBDs). However, the software-
aided prediction of proteins that bind to CaM is hindered by three major issues: (1) the large 
conformational change of CaM upon Ca2+ binding [7; 8; 9], (2) proteins do not bind to Ca2+/CaM via 
defined consensus targeting sequences, but through a diversity of motifs (e.g. 1-5-10 or 1-8-14 or 1-12 
motifs or non-canonical motifs) involving hydrophobic amino acids and basic residues [12], and (3) Ca2+-
independent binding of proteins to CaM occurs via IQ- or IQ-like motifs showing certain degree of 
variability as well [8; 9]. Thus, direct experimental assessment of CaM interaction with each protein target 
is needed.  
Actually, it has been shown that CaM can bind and regulate the functioning of both, amyloid β 
precursor protein (APP) and β-secretase (BACE1; beta-site APP cleaving enzyme 1) (reviewed in [9]), as 
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well as one hallmark of AD such as tau [13] and also Ca2+/CaM-dependent protein kinase II (CaMKII) and 
cyclin-dependent kinase 5 (CDK5) involved in tau hyperphosphorylation [14]. Moreover, in a previous 
work [15] control dot-blot overlay assays suggested the occurrence of direct Aβ1-42 interaction with 
Ca2+/CaM, which could, at least partially, account for calmodulin antagonism of the inhibition of brain 
plasma membrane Ca2+-ATPase by Aβ1-42. However, dot-blot overlay assays neither allow to properly 
quantify the strength of the interaction between Aβ1-42 and CaM, nor to critically assess its functional 
relevance for each protein partner.        
In this work, we have experimentally addressed the study of the binding of Aβ to CaM, both in the 
presence and in the absence of Ca2+ (Ca2+/CaM
  
and
 
apo-CaM respectively), using fluorescence derivatives 
of CaM and Aβ. The results have pointed out that (1) Ca2+/CaM binding to Aβ has a nanomolar 
dissociation constant, (2) the affinity of Aβ for CaM is strongly altered by calcium binding-induced 
changes of CaM conformation, (3) this interaction involves the neurotoxic Aβ domain 25-35, and (4) it 
also significantly slows down Aβ fibrillation.    
 
2. Materials and methods 
 
2.1. Materials 
All reagents and buffer components were of analytical grade purchased from Sigma-Aldrich (St. 
Louis, MO), unless otherwise indicated. T34C and T110C variants of human expressed calmodulin were 
generated and labelled with Badan (6-Bromoacetyl-2-dimethylaminonaphthalene) in the same conditions 
as previously described for the T34C/T110C double mutant [16]. The labelled proteins were HPLC 
purified and freeze-dried. Unlabeled calmodulin from bovine testes was obtained from Sigma-Aldrich. 
Human amyloid β (1-42) HiLyte™-Fluor555 was obtained from AnaSpec (Freemont, CA). Unlabeled 
amyloid β (1-42) and amyloid β (25-35) were synthesized by StabVida (Caparica, Portugal). Lyophilized 
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peptides were dissolved in 1% NH4OH, and then diluted with PBS buffer to desired concentrations. 
Reconstituted peptides were aliquoted and stored at –20°C. 
 
2.2. Fluorescence quenching studies 
Fluorescence measurements were performed using a Cary Eclipse fluorescence spectrophotometer 
(Agilent Technologies) at 25°C in 1 cm quartz cells with both excitation and emission slits of 10 nm.  
Fluorescence titrations of 5 nM Badan-CaM(T34C) or 10 nM Badan-CaM(T110C) with unlabeled 
or labeled Aβ1-42 and Aβ25-35 were carried out by addition of varying amounts of stock solutions of 
amyloid peptides (20 µM and 2 µM) in 50 mM HEPES-KOH (pH 7.4), 100 mM KCl, 2mM MgCl2 and 50 
µM CaCl2 buffer. Fluorescence emission spectra of Badan-CaM were acquired with 385nm excitation 
wavelength. Titrations of 10 nM HiLyte™-Fluor555-Aβ1-42 with unlabeled CaM were performed in a 
“low calcium buffer” containing 50 mM HEPES-KOH (pH 7.4), 100 mM KCl, 2mM MgCl2 and 20 mM 
EGTA buffer, and the fluorescence emission spectra were acquired with excitation wavelength of 525 nm.  
The fluorescence intensity data were corrected for volume changes during titrations, which were 
always <3%. No inner filter corrections were needed in titration data, because the increase of absorbance 
at excitation and emission wavelengths were always <0.002. Each experiment was performed in 
quadruplicate. 
 
2.3. Calcium titration assays 
For calcium titration assays 150 mM HEPES-KOH (pH 7.1), 100 mM KCl, 2mM MgCl2 and 250 
µM EGTA buffer was used. Afterwards, 10 nM of Badan-CaM(T110C) were added. To test the effect of 
β-amyloid peptides, Badan-CaM(T110C) was preincubated with either Aβ1-42 or Aβ25-35 at 37°C for 30 
minutes at an equimolar ratio. Subsequently, CaCl2 was added at increasing amounts and fluorescence was 
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measured with an excitation wavelength of 385 nm and the fluorescence emission spectra were acquired 
from 400 nm to 650 nm, using a Cary Eclipse fluorescence spectrophotometer (Agilent Technologies). 
Fluorescence measurements were performed at 25°C in 1 cm quartz cell with both excitation and emission 
slits of 10 nm. After subtracting the weak buffer fluorescence spectrum, the fluorescence emission spectra 
were corrected for volume changes. Each experiment was performed in quadruplicate. 
 
2.4. Thioflavin T aggregation assays 
The assay was performed as described in Maezawa et al. [17]. Briefly, a 35 µl of a 0.043 µM 
Aβ1-42 solution was mixed with 115 µl of Thioflavin T (ThT) solution (5 µM in 50 mM glycine-NaOH at 
pH 8.5) giving an Aβ1-42 final concentration of 10 µg/ml. When indicated, Aβ1-42 was previously aged 
at 37ºC for 72h, with or without the addition of CaM at equimolar ratio. After mixing with ThT,  
fluorescence emission at 490 nm, using an excitation wavelength of 440 nm [18], was recorded by a 
Varioskan Flash fluorescence spectrophotometer (Thermo Scientific).  
 
2.5. Docking simulations 
Modeling of protein–peptide interactions was performed using the CABS-dock web server 
(http://biocomp.chem.uw.edu.pl/CABSdock) [19; 20]. PDB files for both calmodulin conformations were 
obtained from Uniprot (http://www.uniprot.org/).  
 
2.6. Statistical analysis 
Non-linear regression fits, statistical analysis and plotting of titration data were done using 
OriginPro 8 software.  
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Differences of Aβ1-42 fibrillation among treatments were assessed by analysis of variance with 
Turkey HSD (Honest Significant Difference) multiple comparison test using SigmaStat 3.10 (Systat). 
Significant difference was accepted at the p<0.05 levels. 
 
3. Results 
To quantify and analyze the interaction between CaM and Aβ1-42 peptide, which is one of the 
major hallmarks of AD, we have used fluorescent Badan-CaM derivatives and fluorescence spectroscopy 
measurements. Titration of the fluorescence of 10 nM BadanCaM-110 with Aβ1-42 in a standard buffer 
50 mM HEPES-KOH (pH 7.4),100 mM KCl, 2 mM MgCl2 and 50 µM CaCl2 showed that nanomolar 
concentrations of Aβ elicited a large quenching of Badan-CaM fluorescence (Figure 1A). The dependence 
of quenching data upon Aβ1-42 concentration can be fit well to a one-site binding equation (Figure 1A, 
insert). A dissociation constant of 0.98±0.11 nM was calculated for Aβ dissociation from the Aβ-CaM 
complex. As this Aβ concentration is within the intracellular range reported for non-fibrillar amyloid [21; 
22; 23], this result unraveled that CaM is a novel intracellular high affinity target for Aβ. Furthermore, 
CaM at a 1:1 molar ratio with Aβ1-42 peptide efficiently protected against amyloid fibrils development as 
shown in Figure 1B. 
On these grounds, we decided to experimentally assess whether the Aβ25-35 peptide, which 
contains the neurotoxic domain of the full-length Aβ1-42, is directly involved in the interaction with CaM. 
The results of the BadanCaM(T110C) fluorescence titration with Aβ25-35 are shown in the Figure 1C, 
and like those obtained with Aβ1-42, these data can be fit to the one-site binding equation (Figure 1C, 
insert), yielding a dissociation constant of 0.66±0.07 nM for Aβ25-35 dissociation from the Aβ-CaM 
complex. Therefore, Aβ25-35 binds to CaM even more strongly than the full Aβ1-42 peptide, pointing out 
that the toxic domain of Aβ plays a leading role in the interaction of this peptide with CaM.  
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The CaM conformation largely changes upon saturation with calcium [7; 8]. Results of Figure 1 
were obtained under experimental conditions where CaM was completely saturated with Ca2+, thus 
showing Aβ interaction with Ca2+/CaM. Considering that BadanCaM(T110C) fluorescence is strongly 
dependent on the saturation of CaM by calcium (Figure 2A), we used this property to experimentally 
evaluate the possibility that interaction of CaM with Aβ1-42 and Aβ25-35 peptides could impair the 
affinity of CaM for calcium ions. However, fluorescence data (Figure 2A) pointed out that these peptides 
produced at most only a slight shift in calmodulin's calcium saturation curves, yielding average Ca2+ 
dissociation constants of 0.32±0.01 µM and 0.38±0.01 µM in the presence of Aβ25-35 and Aβ1-42, 
respectively.  These values were only slightly higher than the average 0.30±0.01 µM Ca2+ dissociation 
constant obtained for CaM in this buffer. Nevertheless, owing to the position of Badan near calcium 
binding at sites 3 and 4 of CaM, solely with these data we cannot exclude the possibility that 
BadanCaM(T110C) fluorescence could be differentially affected by calcium binding to sites 1-2 or 3-4. 
Because of the functional relevance of this point, to further assess whether Aβ1-42 altered the extent of 
calcium binding to CaM, we measured the drop of free calcium using the calcium indicator Fura-2 after 
addition of CaM both in the absence and in the presence of Aβ1-42. Results are shown in Figure 2B and 
proved that Aβ1-42 did not reduce the extent of calcium binding to CaM.  
To evaluate the dissociation constant of Aβ1-42 from CaM in the absence of calcium, we cannot 
use BadanCaM(T110C) because of its low fluorescence when calcium concentration falls in the 
nanomolar range (Figure 2A). Therefore, we selected a fluorescence tagged HiLyteTM-Fluor555-Aβ1-42, 
whose fluorescence emission at 560-580 is not significantly altered by changes of calcium concentration 
up to 50 µM. First, as shown in Figure 3A, we confirmed that titration with HiLyteTM-Fluor555-Aβ1-42 
elicited a extent of quenching of BadanCaM(T110C) fluorescence saturated by calcium similar to that 
measured with Aβ1-42 in Figure 1A. Moreover, using non-linear regression the data fit well to a one-site 
binding equation and yielded a dissociation constant of 0.97±0.09 nM Aβ1-42 (Figure 3B), a value which 
is the same obtained from the titration of BadanCaM(T110C) with unlabeled Aβ1-42. These results 
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allowed us to conclude that HiLyteTM-Fluor555 labeling of Aβ1-42 does not alter Aβ-CaM interaction. 
Then, we performed the titration of the fluorescence of HiLyteTM-Fluor555-Aβ1-42 with unlabeled CaM 
in 50 mM HEPES-KOH (pH 7.4), 100 mM KCl, 2mM MgCl2 and 20 mM EGTA, i.e. with the closed apo-
(Ca2+ free)CaM conformation (Figure 3C). The data are fit by nonlinear regression to a one-site binding 
equation and yielded a dissociation constant of 22.1±1.7 nM for CaM (Figure 3D). Since 
BadanCaM(T110C) and HiLyteTM-Fluor555-Aβ1-42 concentrations were fixed (10 nM) during Aβ and 
CaM titrations, the kd value obtained from Figure 3D pointed out that the close conformation of apo-CaM 
has more than 20-fold lower affinity for Aβ than the open 4Ca2+-CaM conformation.  
 
4. Discussion 
This work has demonstrated that neurotoxic Aβ peptides, Aβ1-42 and Aβ25-35, have a relatively 
high affinity for CaM with a calculated dissociation constant ≤1 nM for the Aβ/CaM complex at 25ºC, and 
physiological pH and ionic strength. This result showed that CaM is a novel intracellular high affinity 
target for Aβ because the concentration of non-fibrillar Aβ peptides is within the nanomolar range in the 
brain [21; 22; 23]. It is also to be recalled here that critical concentration values in the submicromolar 
range have been reported for induction of Aβ1-42 fibrillization [24; 25]. Moreover, the dissociation 
constant of Aβ-CaM complex obtained in this work indicates that the affinity of CaM for Aβ is 
approximately 20-fold higher than for human recombinant apo-E3 and –E4, a major risk factor for late 
onset Alzheimer’s disease and also a well-accepted cellular target for Aβ with a dissociation constant 
value of 20 nM [26]. A binding affinity in the low nanomolar range has been calculated using surface 
plasmon resonance for Aβ1-42 interaction with the major intracellular target tau [27].  Noteworthy, the 
Aβ1-42 dissociation constant from Aβ-CaM complex is nearly identical to the reported dissociation 
constant of Aβ from PrPc [28], a cellular prion protein that has been proposed to mediate Aβ-induced 
synaptic dysfunction in the mouse brain [25], and also from glycogen synthase kinase 3α (GSK3α), a 
kinase that mediates hyperphosphorylation of tau and that it is stimulated in vitro by Aβ1-42 [29].  
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The 25-35 domain of Aβ1-42 binds to CaM even strongly than the full Aβ1-42 peptide, pointing 
out that CaM interaction is expected to antagonize, at least partially, the binding of Aβ to other recognized 
intracellular targets which mediate its neurotoxicity. Moreover, since the Aβ25-35 segment forms a 
structural loop that protrudes out of the core structure in Aβ oligomers [30; 31], CaM is expected to have a 
similar affinity for Aβ monomers and oligomers. In addition, CaM at a molar ratio 1:1 with Aβ1-42 
peptide efficiently protected against amyloid fibrils development. Taken all together these results suggest 
a relevant, and up to now overlooked, direct neuroprotective role of CaM against Aβ neurotoxicity in the 
brain. Currently, in vivo experiments are being undertaken to experimentally address this hypothesis in 
neuronal cultures (manuscript in preparation). 
In contrast to the functional impairment of Aβ, our results allowed to conclude that the interaction 
of Aβ with CaM does not alter calcium binding to CaM, despite that the closed conformation of apo-CaM 
has more than 20-fold lower affinity for Aβ than the open 4Ca2+-CaM conformation. 
Docking simulations online using the program CABS Dock yielded two putative sites at the 
central connection helical domain of 4Ca2+-CaM for Aβ25-35 interaction, being one located close to the 
N-terminus domain containing calcium binding sites 1 and 2, and the other located near the C-terminus 
domain containing the calcium binding sites 3 and 4. The lack of significant fluorescence quenching of 
BadanCaM(T34C) by Aβ1-42 (data not shown), while it induced approximately 40% quenching of the 
fluorescence of BadanCaM(T110C), indicated that Aβ binds to a site located at or close to the CaM C-
terminal domain and further apart from the protein N-terminus (Figure 4A). Taking into account that the 
central helical domain of Ca2+/CaM
 
folds over the target domain of cellular signaling proteins linked to 
Alzheimer’s disease modulated by calmodulin [8; 9; 11] and the major role of calmodulin-binding 
proteins in neuronal plasticity and activity [7; 8], it is likely that the interaction between Aβ and Ca2+/CaM
 
will have major functional consequences for brain physiology. Indeed, in a previous work we have shown 
that calmodulin antagonizes amyloid β peptides-mediated inhibition of brain plasma membrane Ca2+-
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ATPase [15]. Moreover, BadanCaM derivatives have been shown to be useful to monitor conformational 
changes not only in CaM, but also those in the CaM-CaM binding proteins interface.  
Docking simulations for Aβ25-35-apoCaM complex showed that most-probable docking 
conformations were completely different from those aforementioned for Ca2+ saturation conditions (Figure 
4B). Since apo-CaM has been reported to co-immunoprecipitate with APP, and to promote ADAM10-
mediated proteolysis of APP through the non-amyloidogenic pathway resulting in sAPPα production [32] 
(thereby antagonizing the stimulation of BACE1-amyloidogenic pathway by CaM), binding of Aβ to apo-
CaM can be seen as a feed-back inhibition mechanism to modulate the production of neurotoxic Aβ 
peptides. 
In summary, this work shows a novel and high affinity interaction between calmodulin and the 
amyloid β peptide, involving the potent neurotoxic 25-35 domain of Aβ which is calcium-dependent, as it 
is modulated by the conformational change induced by calcium binding to CaM. Since the affinity of Aβ1-
42 and Aβ25-35 for Ca2+/CaM is among the higher, if not the highest, reported until now for Aβ 
intracellular or extracellular protein partners, our results open new perspectives to further understand the 
neurotoxic effect of Aβ in different neural cells and also to address the potential of calmodulin and 
calmodulin-derived peptides as therapeutic agents in AD. 
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4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; ThT, Thioflavin T. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
 
Figure legends 
 
FIGURE 1. Calmodulin-Aβ interaction in the presence of calcium. A) Sequential fluorescence 
emission spectra of 10 nM BadanCaM(T110C) were acquired as indicated in the Materials and Methods in 
the absence (bold trace) and presence of indicated concentrations of Aβ1-42 (thin line traces from top to 
bottom). Insert: Non-linear regression analysis of fluorescence quenching (excitation and emission 
wavelengths: 385 and 487nm, respectively) fit to one binding site equation (R2 = 0.992). B) Formation of 
Aβ1-42 (Aβ) fibrils, after incubation of 10 µg Aβ/ml during  72h at 37 ºC (Aβ 72h), were monitored by 
the increase of ThT fluorescence with respect to non-incubated Aβ (Aβ), as indicated in the Materials and 
Methods, in the absence and presence of CaM at a molar ratio 1:1 (* p<0.05). C) Sequential fluorescence 
emission spectra of 10 nM BadanCaM(T110C) were acquired as indicated in the Materials and Methods in 
the absence (bold trace) and presence (thin line traces from top to bottom) of indicated concentrations of 
Aβ25-35. Insert: Non-linear regression analysis of fluorescence quenching (excitation and emission 
wavelengths: 385 and 487nm, respectively) fit to one binding site equation (R2 = 0.994).  
FIGURE 2. Effect of Aβ on calcium binding to calmodulin. A) Calcium dependence of the 
fluorescence of BadanCaM(T110C) in the absence or presence of Aβ1-42 and Aβ25-35. , 
BadanCaM(T110C) (R2 = 0.990); , +Aβ1-42 (R2 = 0.996); , +Aβ25-35) (R2 = 0.993). Excitation and 
emission wavelengths: 385 and 487nm, respectively. B) Free calcium measurements using the calcium 
indicator Fura-2 before and after addition of 2 µM of CaM (), Aβ1-42 (), or CaM+Aβ1-42 (). 
FIGURE 3. Calcium modulates calmodulin-Aβ interaction. A) Quenching of 10 nM 
BadanCaM(T110C) fluorescence upon titration with HiLyteTM-Fluor555-Aβ1-42 (Aβ*). Sequential 
fluorescence emission spectra of 10 nM BadanCaM(T110C) were acquired in the presence of 50µM 
calcium buffer as indicated in the Materials and Methods in the absence (bold trace) and presence of 
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indicated concentrations of HiLyteTM-Fluor555-Aβ1-42 (thin line traces from top to bottom). B) The non-
linear regression analysis of Aβ* quenching titration data (excitation and emission wavelengths: 385 and 
487nm, respectively) fit to a one binding site equation (R2 = 0.991). C) Enhancement of the fluorescence 
of 10 nM HiLyteTM-Fluor555-Aβ1-42 upon titration with unlabeled CaM in “low calcium buffer”, see 
Materials and Methods. Bold trace: fluorescence spectra of 10 nM HiLyteTM-Fluor555-Aβ1-42 in the 
absence of CaM. D) The non-linear regression analysis of the increase of HiLyteTM-Fluor555-Aβ1-42 
fluorescence induced by CaM (excitation and emission wavelengths: 525 and 573nm, respectively) fit to a 
one binding site equation (R2 = 0.997).  
FIGURE 4. Potential CaM binding sites for Aβ25-35 given by selected PDB-model outcomes of 
simulations performed with the CABS Dock web server. Putative binding site of Aβ25-35 (light red) to 
CaM (light blue) in the conformations adopted in the presence (A, Ca2+/CaM) and in the absence (B, apo-
CaM) of calcium. The approximate positions of Badan in the fluorescent derivatives of CaM used in this 
work are highlighted as circles and labeled as T34C and T110C. 
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Highlights: 
 
• Aβ binds with high affinity to calmodulin through the Aβ25-35 domain. 
 
• Aβ has higher affinity for Ca2+-saturated calmodulin. 
 
• Calmodulin is one of the cellular targets with highest affinity for Aβ. 
 
• Aβ-Calmodulin interaction slows down Aβ fibrillation. 
 
